Equifund CEO, Jordan Gillissie sits down with Ivan Lo, CEO of Breath Diagnostics, for an in-depth corporate update.
On this insightful call, we answer questions such as:
- What is Breath Diagnostics and what does it do?
(@ 1:00 mark) - Why is pneumonia on your radar and why is it a problem worth solving?
(@ 10:00 mark and 26:20 mark) - Breath recently received “Breakthrough” designation from the FDA. What does that mean? And is “Breakthrough Designation” common in med-tech?
(@ 3:20 mark & 16:00 mark)- Are there potential cost savings?
(@ 27:00 mark)
- Are there potential cost savings?
- Does it potentially increase the value, or market cap, of your business?
(@ 33:30 mark) - What does the next 18 months look like?
(@ 31:00 mark) - Does the recent FDA accomplishment impact your potential go public strategy?
(@ 36:00 mark)
Learn all this and get more insight into Breath Diagnostics and its future plans on this webinar.